Bioresorbable Scaffolds: Clinical Outcomes and Considerations.

Bioresorbable scaffolds (BRS) have been engineered to eliminate the theoretic stimulus to late coronary events, a caveat of conventional metallic drug-eluting stents (DESs). Outcome benefits of BRSs over current-generation DESs are expected to accrue after complete bioresorption. Before this timeframe, BRSs need to prove at least similarly safe and effective compared with DESs. Several randomized studies of the Absorb BRS have been made available. Several manufacturers are at the beginning of their line of clinical development of competing BRSs. This article reviews the contemporary clinical outcomes of the Absorb scaffold, and provides an updated state of the art on the other players in the BRS arena.